Shelton Capital Management Increases Stock Position in Stryker Corporation $SYK

Shelton Capital Management increased its position in shares of Stryker Corporation (NYSE:SYK) by 13.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,800 shares of the medical technology company’s stock after purchasing an additional 1,267 shares during the quarter. Shelton Capital Management’s holdings in Stryker were worth $4,273,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Mid American Wealth Advisory Group Inc. bought a new position in shares of Stryker in the second quarter valued at approximately $26,000. Elevation Point Wealth Partners LLC bought a new position in Stryker in the 2nd quarter valued at $28,000. Sachetta LLC increased its position in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 27 shares during the last quarter. Ridgewood Investments LLC raised its stake in shares of Stryker by 48.4% during the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after purchasing an additional 30 shares during the period. Finally, Ransom Advisory Ltd purchased a new position in shares of Stryker in the 1st quarter worth about $37,000. 77.09% of the stock is owned by institutional investors.

Stryker Trading Up 0.2%

Shares of SYK stock opened at $371.95 on Tuesday. The stock has a market capitalization of $142.24 billion, a price-to-earnings ratio of 49.27, a PEG ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The company’s fifty day simple moving average is $368.77 and its two-hundred day simple moving average is $380.08.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the prior year, the firm posted $2.87 EPS. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Insider Transactions at Stryker

In other news, CFO Preston Wendell Wells sold 165 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the sale, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. This represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the transaction, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 522,118 shares of company stock valued at $185,381,932. 5.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $448.00 price objective on shares of Stryker in a report on Friday, November 14th. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a research report on Tuesday, November 25th. UBS Group set a $408.00 price target on shares of Stryker in a research note on Monday, October 13th. Evercore ISI lowered their price target on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $435.00 target price on shares of Stryker in a research report on Friday, November 14th. Twelve research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $433.78.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.